BR0014107A - Formulação de grânulo, processo para preparar a mesma, uso de formulação de grânulo, método para tratar do doenças do sistema nervoso central, tais como psicoses, em particular esquizofrenia, kit, e, sache - Google Patents

Formulação de grânulo, processo para preparar a mesma, uso de formulação de grânulo, método para tratar do doenças do sistema nervoso central, tais como psicoses, em particular esquizofrenia, kit, e, sache

Info

Publication number
BR0014107A
BR0014107A BR0014107-0A BR0014107A BR0014107A BR 0014107 A BR0014107 A BR 0014107A BR 0014107 A BR0014107 A BR 0014107A BR 0014107 A BR0014107 A BR 0014107A
Authority
BR
Brazil
Prior art keywords
granule formulation
nervous system
central nervous
sache
psychosis
Prior art date
Application number
BR0014107-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel Body Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR0014107A publication Critical patent/BR0014107A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
BR0014107-0A 1999-09-21 2000-09-18 Formulação de grânulo, processo para preparar a mesma, uso de formulação de grânulo, método para tratar do doenças do sistema nervoso central, tais como psicoses, em particular esquizofrenia, kit, e, sache BR0014107A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation
PCT/GB2000/003598 WO2001021179A1 (en) 1999-09-21 2000-09-18 Quetiapine granules

Publications (1)

Publication Number Publication Date
BR0014107A true BR0014107A (pt) 2002-08-20

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014107-0A BR0014107A (pt) 1999-09-21 2000-09-18 Formulação de grânulo, processo para preparar a mesma, uso de formulação de grânulo, método para tratar do doenças do sistema nervoso central, tais como psicoses, em particular esquizofrenia, kit, e, sache

Country Status (37)

Country Link
US (3) US6599897B1 (https=)
EP (1) EP1218009B1 (https=)
JP (1) JP2003509461A (https=)
KR (1) KR100748823B1 (https=)
CN (3) CN1188130C (https=)
AR (1) AR032596A1 (https=)
AT (1) ATE288272T1 (https=)
AU (1) AU776292B2 (https=)
BG (1) BG65469B1 (https=)
BR (1) BR0014107A (https=)
CA (1) CA2383131A1 (https=)
CO (1) CO5180585A1 (https=)
CZ (1) CZ301585B6 (https=)
DE (1) DE60017923T2 (https=)
DK (1) DK1218009T3 (https=)
EE (1) EE200200150A (https=)
EG (1) EG24226A (https=)
ES (1) ES2235941T3 (https=)
GB (2) GB9922271D0 (https=)
HK (1) HK1047706B (https=)
HU (1) HUP0203531A3 (https=)
IL (2) IL148440A0 (https=)
IS (1) IS2139B (https=)
MX (1) MXPA02002627A (https=)
MY (1) MY130208A (https=)
NO (1) NO320908B1 (https=)
NZ (1) NZ517549A (https=)
PL (1) PL198824B1 (https=)
PT (1) PT1218009E (https=)
RU (1) RU2256453C2 (https=)
SI (1) SI1218009T1 (https=)
SK (1) SK286884B6 (https=)
TR (1) TR200200716T2 (https=)
TW (1) TWI226832B (https=)
UA (1) UA73529C2 (https=)
WO (1) WO2001021179A1 (https=)
ZA (1) ZA200201709B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
WO2006117700A2 (en) * 2005-04-21 2006-11-09 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
CA2657202A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
WO2008052354A1 (en) * 2006-11-03 2008-05-08 University Of Saskatchewan Method of treating demyelination diseases
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
ATE480227T1 (de) * 2007-02-14 2010-09-15 Lesvi Laboratorios Sl Pharmazeutische zusammensetzungen mit quetiapinfumarat
ES2700994T3 (es) * 2008-02-27 2019-02-20 Intercontinental Great Brands Llc Confitería de multirregión
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
AU2021263558B2 (en) * 2020-04-29 2026-02-26 Stepan Company Solid compositions containing amine, protonated amine or quaternary ammonium compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
ES2054259T3 (es) * 1989-08-31 1994-08-01 Takeda Chemical Industries Ltd Composicion de vitamina b12.
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
ATE163927T1 (de) * 1992-11-09 1998-03-15 Knoll Ag 1,4-benzothiazepine verwendbar als neurologische mittel
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
HUP0203531A3 (en) 2004-12-28
PL357369A1 (en) 2004-07-26
SK3722002A3 (en) 2002-07-02
ZA200201709B (en) 2003-05-28
HK1047706A1 (en) 2003-03-07
MXPA02002627A (es) 2002-07-30
SI1218009T1 (en) 2005-06-30
UA73529C2 (uk) 2005-08-15
SK286884B6 (sk) 2009-07-06
IS2139B (is) 2006-08-15
IS6308A (is) 2002-03-19
EP1218009A1 (en) 2002-07-03
AU7302300A (en) 2001-04-24
CN1626094A (zh) 2005-06-15
MY130208A (en) 2007-06-29
IL148440A (en) 2007-07-04
TR200200716T2 (tr) 2002-06-21
NO320908B1 (no) 2006-02-13
TWI226832B (en) 2005-01-21
JP2003509461A (ja) 2003-03-11
NO20021394D0 (no) 2002-03-20
KR100748823B1 (ko) 2007-08-13
CN1899288A (zh) 2007-01-24
CN1188130C (zh) 2005-02-09
NZ517549A (en) 2003-10-31
EE200200150A (et) 2003-04-15
CN1374867A (zh) 2002-10-16
EP1218009B1 (en) 2005-02-02
GB0021406D0 (en) 2000-10-18
US20060159768A1 (en) 2006-07-20
DK1218009T3 (da) 2005-05-09
EG24226A (en) 2008-11-10
BG106509A (en) 2002-12-29
GB9922271D0 (en) 1999-11-17
WO2001021179A1 (en) 2001-03-29
US7022692B2 (en) 2006-04-04
PL198824B1 (pl) 2008-07-31
CO5180585A1 (es) 2002-07-30
ATE288272T1 (de) 2005-02-15
DE60017923D1 (de) 2005-03-10
IL148440A0 (en) 2002-09-12
US6599897B1 (en) 2003-07-29
DE60017923T2 (de) 2006-01-12
PT1218009E (pt) 2005-05-31
CA2383131A1 (en) 2001-03-29
KR20020033186A (ko) 2002-05-04
US20040228914A1 (en) 2004-11-18
CZ301585B6 (cs) 2010-04-21
ES2235941T3 (es) 2005-07-16
HUP0203531A2 (hu) 2003-02-28
NO20021394L (no) 2002-03-20
AU776292B2 (en) 2004-09-02
HK1047706B (en) 2005-06-10
CZ2002974A3 (cs) 2002-06-12
CN1331472C (zh) 2007-08-15
BG65469B1 (bg) 2008-09-30
AR032596A1 (es) 2003-11-19
RU2256453C2 (ru) 2005-07-20

Similar Documents

Publication Publication Date Title
BR0014107A (pt) Formulação de grânulo, processo para preparar a mesma, uso de formulação de grânulo, método para tratar do doenças do sistema nervoso central, tais como psicoses, em particular esquizofrenia, kit, e, sache
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
BR0315681A (pt) Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
BR0113291A (pt) steres de aporfina e seu uso em terapia
BR9712321A (pt) Aminotiofenocarboxamidas
PT751939E (pt) Naftilamidas como agentes para o sistema nervoso central
BR0212841A (pt) Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
BRPI0415050A (pt) composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
BR0013281A (pt) Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais
PT97446A (pt) Processo para a preparacao de um derivado de tienobenzodiazepina, util como produto farmaceutico
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0116505A (pt) Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR9906169A (pt) Derivados de pirrolo [1, 2-a] pirazina como ligandos sht 1a
PT98148A (pt) Processo de preparacao de r(+)-2-{4-{(tetra-hidro-2-furanil)carbonil}-1-piperazinil}-6,7-dimetoxi-4-quinazolinamina e de seus sais farmaceuticamente aceitaveis,substancialmente isentos de enantiomero s(-) e de composicoes farmaceuticas
BR0012764A (pt) Composto, processo para preparar um composto, composição farmacêutica, uso de um composto e método de tratar um paciente humano ou animal
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BR9910035A (pt) Derivados de guanidina
BR9808290A (pt) Composto, composição farmacêutica, processo de tratar infecções bacterianas em seres humanos e animais, uso de um composto, e, processo para sua preparação
BRPI0411868A (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BR0210034A (pt) Conjunto de partes, método para tratamento de trombose, uso de um composto, formulação farmacêutica, uso e processo para preparação da mesma, e, composto
BRPI0016138B8 (pt) formulação farmacêutica adequada para a administração intranasal, uso de zolmitriptan, e, dispositivo de administração intranasal

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI NO 2013 DE 04/08/2009

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O,13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.